# Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol

> **NCT03216525** · PHASE3 · RECRUITING · sponsor: **Brigham and Women's Hospital** · enrollment: 136 (estimated)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Alvimopan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03216525
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-10-01
- **Primary completion:** 2023-12-01
- **Final completion:** 2024-06-01
- **Target enrollment:** 136 (ESTIMATED)
- **Last updated:** 2023-09-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03216525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03216525, "Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03216525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*